| Autor: |
Dayyani F; Department of Medicine, University of California Irvine, Orange, CA 92868, USA., Smith BR; Department of Surgery, University of California Irvine, Orange, CA 92868, USA., Nguyen NT; Department of Surgery, University of California Irvine, Orange, CA 92868, USA., Daly S; Department of Surgery, University of California Irvine, Orange, CA 92868, USA., Hinojosa MW; Department of Surgery, University of California Irvine, Orange, CA 92868, USA., Seyedin SN; Department of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA., Kuo J; Department of Radiation Oncology, University of California Irvine, Orange, CA 92868, USA., Samarasena JB; Department of Medicine, University of California Irvine, Orange, CA 92868, USA., Lee JG; Department of Medicine, University of California Irvine, Orange, CA 92868, USA., Taylor TH; Department of Epidemiology, University of California Irvine, Irvine, CA 92617, USA., Cho MT; Department of Medicine, University of California Irvine, Orange, CA 92868, USA., Senthil M; Department of Surgery, University of California Irvine, Orange, CA 92868, USA. |
| Abstrakt: |
Current guidelines recommend neoadjuvant (NAC) and/or adjuvant chemotherapy for locally advanced gastric cancers (LAGCs). However, the choice and duration of NAC regimen is standardized, rather than personalized to biologic response, despite the availability of several different classes of agents for the treatment of gastric cancer (GC). The current trial will use a tumor-informed ctDNA assay (Signatera™) and monitor response to NAC. Based on ctDNA kinetics, the treatment regimen is modified. This is a prospective single center, single-arm, open-label study in clinical stage IB-III GC. ctDNA is measured at baseline and repeated every 8 weeks. Imaging is performed at the same intervals. The primary end point is the feasibility of this approach, defined as percentage of patients completing gastrectomy. |
